Fig. 8

The combination treatment of cisplatin and decitabine improves efficacy of anti-HCC therapeutic in xenograft mice models a Tumor volume curves and b Representative of tumors from xenograft mice treated with cisplatin (5 mpk) and decitabine (1 or 2mpk) (N = 4). c PARP activation form (cleaved PARP) and ASS1 expression levels in tumor tissues of xenograft mice treated with cisplatin and decitabine by western blot assay. d-e Relative quantitative expression analysis of cleaved PARP and ASS1. ^*P < 0.05 compared to control group